L-carnitine supplementation for the management of fatigue in patients with cancer: An Eastern Cooperative Oncology Group phase III, randomized, double-blind, placebo-controlled trial

Ricardo A. Cruciani*, Jenny J. Zhang, Judith Manola, David Cella, Bilal Ansari, Michael J. Fisch

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

63 Scopus citations

Abstract

Purpose: L-carnitine, a popular complementary and alternative medicine product, is used by patients with cancer for the treatment of fatigue, the most commonly reported symptom in this patient population. The purpose of this study was to determine the efficacy of L-carnitine supplementation as a treatment for fatigue in patients with cancer. Patients and Methods: In this double-blind, placebo-controlled trial, patients with invasive malignancies and fatigue were randomly assigned to either 2 g/d of L-carnitine oral supplementation or matching placebo. The primary end point was the change in average daily fatigue from baseline to week 4 using the Brief Fatigue Inventory (BFI). Results: Three hundred seventy-six patients were randomly assigned to treatment with L-carnitine supplementation or placebo. L-carnitine supplementation resulted in significant carnitine plasma level increase by week 4. The primary outcome, fatigue, measured using the BFI, improved in both arms compared with baseline (L-carnitine: -0.96, 95% CI, -1.32 to -0.60; placebo: -1.11, 95% CI -1.44 to -0.78). There were no statistically significant differences between arms ( P = .57). Secondary outcomes, including fatigue measured by the Functional Assessment of Chronic Illness Therapy-Fatigue instrument, depression, and pain, did not show significant difference between arms. A separate analysis of patients who were carnitine-deficient at baseline did not show statistically significant improvement in fatigue or other outcomes after L-carnitine supplementation. Conclusion: Four weeks of 2 g of L-carnitine supplementation did not improve fatigue in patients with invasive malignancies and good performance status.

Original languageEnglish (US)
Pages (from-to)3864-3869
Number of pages6
JournalJournal of Clinical Oncology
Volume30
Issue number31
DOIs
StatePublished - Nov 1 2012

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'L-carnitine supplementation for the management of fatigue in patients with cancer: An Eastern Cooperative Oncology Group phase III, randomized, double-blind, placebo-controlled trial'. Together they form a unique fingerprint.

Cite this